HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NIS-793

monoclonal antibody targeting TGF-beta

Also Known As:

NIS793

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NIS-793: 2
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NIS-793: 2
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        NIS-793: 2

Related Diseases

1.	Neoplasms (Cancer) 11/29/2023 - "In patients with advanced solid tumors, proof of mechanism of NIS793 is supported by evidence of target engagement and TGF-β pathway inhibition. " 11/29/2023 - "This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. " 11/29/2023 - "Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors." 10/01/2023 - "This study provides scientific rationale for evaluation of NIS793 with FOLFIRINOX or gemcitabine/nanoparticle (albumin-bound) paclitaxel chemotherapy backbone in the clinical setting and supports the concept of manipulating cancer cell plasticity to increase the efficacy of combination therapy regimens."
2.	Pancreatic Neoplasms (Pancreatic Cancer) 10/01/2023 - "We evaluated the TGFβ-blocking antibody NIS793 in combination with gemcitabine/nanoparticle (albumin-bound)-paclitaxel or FOLFIRINOX (folinic acid [FOL], 5-fluorouracil [F], irinotecan [IRI] and oxaliplatin [OX]) in orthotopic pancreatic cancer models. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 11/29/2023 - "Three partial responses were reported: one in renal cell carcinoma (NIS793 30 mg/kg Q2W plus spartalizumab 400 mg Q4W), and two in the MSS-CRC expansion cohort. "

Related Drugs and Biologics

1.	Gemcitabine
2.	Albumin-Bound Paclitaxel
3.	folfirinox
4.	Monoclonal Antibodies
5.	spartalizumab
6.	Fluorouracil (Carac)
7.	Leucovorin (Folinic Acid)
8.	Oxaliplatin (Eloxatin)
9.	Irinotecan (Camptosar)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)